α-globin as a molecular target in the treatment of β-thalassemia

Blood

Volumn 125, Issue 24, 2015, Pages 3694-3701

  Mettananda, Sachith ^a,b   Gibbons, Richard J ^a   Higgs, Douglas R ^a,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF KELANIYA   (Sri Lanka)

^c NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; DECITABINE; DOUBLE STRANDED RNA; HEMOGLOBIN ALPHA CHAIN; HEMOGLOBIN BETA CHAIN; HEMOGLOBIN E; REACTIVE OXYGEN METABOLITE; RNA; ROMIDEPSIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; VORINOSTAT;

ALPHA THALASSEMIA; ARTICLE; BETA THALASSEMIA; CHROMOSOME 16; CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; DNA MODIFICATION; GENE EXPRESSION; GENE FREQUENCY; GENE TARGETING; GENETIC ANALYSIS; GENOME; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN SYNTHESIS; HISTOPATHOLOGY; HUMAN; INHERITANCE; MOLECULAR BIOLOGY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); POSTTRANSCRIPTIONAL GENE SILENCING; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; RISK FACTOR; RNA EDITING; RNA INTERFERENCE; ANIMAL; BETA-THALASSEMIA; DOWN REGULATION; DRUG EFFECTS; GENE THERAPY; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROCEDURES;

ALPHA-GLOBINS; ANIMALS; BETA-THALASSEMIA; DOWN-REGULATION; GENETIC THERAPY; HUMANS; MOLECULAR TARGETED THERAPY; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84931275300     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-03-633594     Document Type: Article

References (96)

1. Higgs DR, Engel JD, Stamatoyannopoulos G. Thalassaemia. Lancet. 2012;379(9813):373-383.
2. Weatherall DJ. The challenge of haemoglobinopathies in resource-poor countries. Br J Haematol. 2011;154(6):736-744.
3. Weatherall DJ. The inherited diseases of hemoglobin are an emerging global health burden. Blood. 2010;115(22):4331-4336.
4. Michlitsch J, Azimi M, Hoppe C, et al. Newborn screening for hemoglobinopathies in California. Pediatr Blood Cancer. 2009;52(4):486-490.
5. Nienhuis AW, Nathan DG. Pathophysiology and Clinical Manifestations of the β-Thalassemias. Cold Spring Harb Perspect Med. 2012;2(12): a011726.
6. Porter JB. Pathophysiology of transfusional iron overload: contrasting patterns in thalassemia major and sickle cell disease. Hemoglobin. 2009; 33(Suppl 1):S37-S45.
7. Cao A, Moi P, Galanello R. Recent advances in β-thalassemias. Pediatr Rep. 2011;3(2):e17.
8. Gambari R. Alternative options for DNA-based experimental therapy of β-thalassemias. Expert Opin Biol Ther. 2012;12(4):443-462.
9. Dong A, Rivella S, Breda L. Gene therapy for hemoglobinopathies: progress and challenges. Transl Res. 2013;161(4):293-306.
10. Cavazzana-Calvo M, Payen E, Negre O, et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassemias. Nature. 2010;467(7313):318-322.
11. α-t87q-globin vector (LentiGlobin BB305 Drug Product) [abstract]. Blood. 2014;124(21). Abstract 549.
12. Persons DA. Gene therapy: Targeting β-thalassemias. Nature. 2010;467(7313): 277-278.
13. Thein SL. The emerging role of fetal hemoglobin induction in non-transfusion-dependent thalassemia. Blood Rev. 2012;26(Suppl 1): S35-S39.
14. Musallam KM, Taher AT, Cappellini MD, Sankaran VG. Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemias. Blood. 2013;121(12):2199-2212, quiz 2372.
15. Manchinu MF, Marongiu MF, Poddie D, et al. In vivo activation of the human δ-globin gene: the therapeutic potential in β-thalassemic mice. Haematologica. 2014;99(1):76-84.
16. Nathan DG, Gunn RB. Thalassemia: the consequences of unbalanced hemoglobin synthesis. Am J Med. 1966;41(5):815-830.
17. Weatherall DJ, Clegg JB. The Thalassanemia Syndromes. 4th ed. Oxford: Blackwell Science; 2001.
18. Higgs D, Wood W. Erythropoiesis. In: Hoffbrand A, Catovsky D, Tuddenham E, Green A, eds. Postgraduate Haematology. NJ: Wiley-Blackwell; 2011:12-25.
19. Thein SL. The molecular basis of β-thalassemias. Cold Spring Harb Perspect Med. 2013;3(5): a011700.
20. Orkin SH, Kazazian HH Jr, Antonarakis SE, Ostrer H, Goff SC, Sexton JP. Abnormal RNA processing due to the exon mutation of beta E-globin gene. Nature. 1982;300(5894):768-769.
21. Olivieri NF, Pakbaz Z, Vichinsky E. Hb E/betathalassaemia: a common & clinically diverse disorder. Indian J Med Res. 2011;134:522-531.
22. Ribeil JA, Arlet JB, Dussiot M, Moura IC, Courtois G, Hermine O. Ineffective erythropoiesis in β-thalassemias. ScientificWorldJournal. 2013; 2013:394295.
23. Fessas P. Inclusions of hemoglobin erythroblasts and erythrocytes of thalassemia. Blood. 1963;21: 21-32.
24. Fessas P, Loukopoulos D, Thorell B. Absorption Spectra of Inclusion Bodies in Beta-Thalassemia. Blood. 1965;25:105-109.
25. Fessas P, Loukopoulos D, Kaltsoya A. Peptide analysis of the inclusions of erythroid cells in betathalassemia. Biochim Biophys Acta. 1966;124(2): 430-432.
26. Yu X, Kong Y, Dore LC, et al. An erythroid chaperone that facilitates folding of alph-globin subunits for hemoglobin synthesis. J Clin Invest. 2007;117(7):1856-1865.
27. Shinar E, Rachmilewitz EA. Haemoglobinopathies and red cell membrane function. Baillieres Clin Haematol. 1993;6(2):357-369.
28. Voon HP, Vadolas J. Controlling alph-globin: a review of alph-globin expression and its impact on beta-thalassemia. Haematologica. 2008; 93(12):1868-1876.
29. Shaeffer JR. ATP-dependent proteolysis of hemoglobin alpha chains in beta-thalassemic hemolysates is ubiquitin-dependent. J Biol Chem. 1988;263(27):13663-13669.
30. Nagababu E, Rifkind JM. Heme degradation by reactive oxygen species. Antioxid Redox Signal. 2004;6(6):967-978.
31. Nagababu E, Fabry ME, Nagel RL, Rifkind JM. Heme degradation and oxidative stress in murine models for hemoglobinopathies: thalassemia, sickle cell disease and hemoglobin C disease. Blood Cells Mol Dis. 2008;41(1):60-66.
32. Khandros E, Thom CS, D'Souza J, Weiss MJ. Integrated protein quality-control pathways regulate free α-globin in murine β-thalassemias. Blood. 2012;119(22):5265-5275.
33. Schrier SL. Pathophysiology of the thalassemias. The Albion Walter Hewlett Award presentation. West J Med. 1997;167(2):82-89.
34. Schrier SL. Pathophysiology of thalassemia. Curr Opin Hematol. 2002;9(2):123-126.
35. Yuan J, Kannan R, Shinar E, Rachmilewitz EA, Low PS. Isolation, characterization, and immunoprecipitation studies of immune complexes from membranes of β-thalassemic erythrocytes. Blood. 1992;79(11):3007-3013.
36. Fujisawa T, Takeda K, Ichijo H. ASK family proteins in stress response and disease. Mol Biotechnol. 2007;37(1):13-18.
37. Schrier SL, Centis F, Verneris M, Ma L, Angelucci E. The role of oxidant injury in the pathophysiology of human thalassemias. Redox Rep. 2003;8(5):241-245.
38. Arlet JB, Ribeil JA, Guillem F, et al. HSP70 sequestration by free α-globin promotes ineffective erythropoiesis in β-thalassemias. Nature. 2014;514(7521):242-246.
39. Danjou F, Anni F, Galanello R. Beta-thalassemia: from genotype to phenotype. Haematologica. 2011;96(11):1573-1575.
40. Borg J, Papadopoulos P, Georgitsi M, et al. Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobin. Nat Genet. 2010;42(9):801-805.
41. Liu D, Zhang X, Yu L, et al. KLF1 mutations are relatively more common in a thalassemia endemic region and ameliorate the severity of β-thalassemias. Blood. 2014;124(5):803-811.
42. Thein SL. Genetic modifiers of the betahaemoglobinopathies. Br J Haematol. 2008; 141(3):357-366.
43. Thein SL. Genetic association studies in β-hemoglobinopathies. Hematology Am Soc Hematol Educ Program. 2013;2013:354-361.
44. Bauer DE, Kamran SC, Orkin SH. Reawakening fetal hemoglobin: prospects for new therapies for the β-globin disorders. Blood. 2012;120(15): 2945-2953.
45. Suzuki M, Yamamoto M, Engel JD. Fetal globin gene repressors as drug targets for molecular therapies to treat the β-globinopathies. Mol Cell Biol. 2014;34(19):3560-3569.
46. Fessas P, Stamatoyannopoulos G, Karaklis A. Hereditary persistence of foetal haemoglobin and its combination with alpha and beta-thalassaemia. In: 8th Congress of European Society of Haematology. Vienna: Karger; 1961:302.
47. Kan YW, Nathan DG. Mild thalassemia: the result of interactions of alpha and beta thalassemia genes. J Clin Invest. 1970;49(4):635-642.
48. Weatherall DJ. The definition and epidemiology of non-transfusion-dependent thalassemia. Blood Rev. 2012;26(Suppl 1):S3-S6.
49. Wainscoat JS, Kanavakis E, Wood WG, et al. Thalassaemia intermedia in Cyprus: the interaction of alpha and beta thalassaemia. Br J Haematol. 1983;53(3):411-416.
50. Wainscoat JS, Old JM, Weatherall DJ, Orkin SH. The molecular basis for the clinical diversity of beta thalassaemia in Cypriots. Lancet. 1983; 1(8336):1235-1237.
51. Furbetta M, Tuveri T, Rosatelli C, et al. Molecular mechanism accounting for milder types of thalassemia major. J Pediatr. 1983;103(1):35-39.
52. Thein SL, Hesketh C, Wallace RB, Weatherall DJ. The molecular basis of thalassaemia major and thalassaemia intermedia in Asian Indians: application to prenatal diagnosis. Br J Haematol. 1988;70(2):225-231.
53. Oggiano L, Dore F, Pistidda P, et al. Homozygous beta zero-39 mutation with thalassemia intermedia in northern Sardinia: clinical, hematological and molecular analysis. Hemoglobin. 1988;12(5-6):673-680.
54. Galanello R, Dessi E, Melis MA, et al. Molecular analysis of beta zero-thalassemia intermedia in Sardinia. Blood. 1989;74(2):823-827.
55. Gringras P, Wonke B, Old J, et al. Effect of alpha thalassaemia trait and enhanced gamma chain production on disease severity in beta thalassaemia major and intermedia. Arch Dis Child. 1994;70(1):30-34.
56. Camaschella C, Mazza U, Roetto A, et al. Genetic interactions in thalassemia intermedia: analysis of beta-mutations, alpha-genotype, gammapromoters, and beta-LCR hypersensitive sites 2 and 4 in Italian patients. Am J Hematol. 1995; 48(2):82-87.
57. Rund D, Oron-Karni V, Filon D, Goldfarb A, Rachmilewitz E, Oppenheim A. Genetic analysis of beta-thalassemia intermedia in Israel: diversity of mechanisms and unpredictability of phenotype. Am J Hematol. 1997;54(1):16-22.
58. Ho PJ, Hall GW, Luo LY, Weatherall DJ, Thein SL. Beta-thalassaemia intermedia: is it possible consistently to predict phenotype from genotype? Br J Haematol. 1998;100(1):70-78.
59. Winichagoon P, Fucharoen S, Chen P, Wasi P. Genetic factors affecting clinical severity in betathalassemia syndromes. J Pediatr Hematol Oncol. 2000;22(6):573-580.
60. 0 thalassemia by genetic modifiers. Blood. 2009;114(18): 3935-3937.
61. Badens C, Joly P, Agouti I, et al. Variants in genetic modifiers of β-thalassemias can help to predict the major or intermedia type of the disease. Haematologica. 2011;96(11):1712-1714.
62. Bandyopadhyay S, Roychowdhury K, Chandra S, Das M, Dasgupta UB. Variable severity of beta-thalassemia patients of eastern India: effect of alpha-thalassemia and xmnI polymorphism. Clin Exp Med. 2001;1(3):155-159.
63. Premawardhena A, Fisher CA, Olivieri NF, et al. Haemoglobin E beta thalassaemia in Sri Lanka. Lancet. 2005;366(9495):1467-1470.
64. Suresh S, Fisher C, Ayyub H, et al. Alpha thalassaemia and extended alpha globin genes in Sri Lanka. Blood Cells Mol Dis. 2013;50(2):93-98.
65. Sharma V, Saxena R. Effect of alpha-gene numbers on phenotype of HbE/beta thalassemia patients. Ann Hematol. 2009;88(10):1035-1036.
66. Sripichai O, Munkongdee T, Kumkhaek C, Svasti S, Winichagoon P, Fucharoen S. Coinheritance of the different copy numbers of alph-globin gene modifies severity of beta-thalassemia/Hb E disease. Ann Hematol. 2008;87(5):375-379.
67. Premawardhena A, Fisher CA, Olivieri NF, et al. A novel molecular basis for beta thalassemia intermedia poses new questions about its pathophysiology. Blood. 2005;106(9):3251-3255.
68. Sollaino MC, Paglietti ME, Perseu L, Giagu N, Loi D, Galanello R. Association of a globin gene quadruplication and heterozygous b thalassemia in patients with thalassemia intermedia. Haematologica. 2009;94(10):1445-1448.
69. Origa R, Sollaino MC, Borgna-Pignatti C, et al. α-globin gene quadruplication and heterozygous β-thalassemias: a not so rare cause of thalassemia intermedia. Acta Haematol. 2014;131(3):162-164.
70. Harteveld CL, Higgs DR. Alpha-thalassaemia. Orphanet J Rare Dis. 2010;5:13.
71. Chaisue C, Kitcharoen S, Wilairat P, Jetsrisuparb A, Fucharoen G, Fucharoen S. alpha/beta-Globin mRNA ratio determination by multiplex quantitative real-time reverse transcription-polymerase chain reaction as an indicator of globin gene function. Clin Biochem. 2007;40(18): 1373-1377.
72. Higgs DR, Wood WG. Long-range regulation of alpha globin gene expression during erythropoiesis. Curr Opin Hematol. 2008;15(3): 176-183.
73. De Gobbi M, Anguita E, Hughes J, et al. Tissue-specific histone modification and transcription factor binding in alpha globin gene expression. Blood. 2007;110(13):4503-4510.
74. Vernimmen D, Marques-Kranc F, Sharpe JA, et al. Chromosome looping at the human alpha-globin locus is mediated via the major upstream regulatory element (HS -40). Blood. 2009; 114(19):4253-4260.
75. Garrick D, De Gobbi M, Samara V, et al. The role of the polycomb complex in silencing alph-globin gene expression in nonerythroid cells. Blood. 2008;112(9):3889-3899.
76. Vernimmen D, Lynch MD, De Gobbi M, et al. Polycomb eviction as a new distant enhancer function. Genes Dev. 2011;25(15):1583-1588.
77. Higgs DR, Sharpe JA, Wood WG. Understanding alpha globin gene expression: a step towards effective gene therapy. Semin Hematol. 1998; 35(2):93-104.
78. Higgs DR, Garrick D, Anguita E, et al. Understanding alph-globin gene regulation: Aiming to improve the management of thalassemia. Ann N Y Acad Sci. 2005;1054: 92-102.
79. Chang KH, Fang X, Wang H, et al. Epigenetic modifications and chromosome conformations of the beta globin locus throughout development. Stem Cell Rev. 2013;9(4):397-407.
80. Hannon GJ. RNA interference. Nature. 2002; 418(6894):244-251.
81. Gavrilov K, Saltzman WM. Therapeutic siRNA: principles, challenges, and strategies. Yale J Biol Med. 2012;85(2):187-200.
82. Deng Y, Wang CC, Choy KW, et al. Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies. Gene. 2014;538(2):217-227.
83. Voon HP, Wardan H, Vadolas J. siRNA-mediated reduction of alph-globin results in phenotypic improvements in beta-thalassemic cells. Haematologica. 2008;93(8):1238-1242.
84. Xie SY, Ren ZR, Zhang JZ, et al. Restoration of the balanced alpha/betα-globin gene expression in beta654-thalassemia mice using combined RNAi and antisense RNA approach. Hum Mol Genet. 2007;16(21):2616-2625.
85. Xie SY, Li W, Ren ZR, Huang SZ, Zeng F, Zeng YT. Correction of β654-thalassaemia mice using direct intravenous injection of siRNA and antisense RNA vectors. Int J Hematol. 2011; 93(3):301-310.
86. Kanasty R, Dorkin JR, Vegas A, Anderson D. Delivery materials for siRNA therapeutics. Nat Mater. 2013;12(11):967-977.
87. Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, Anderson DG. Non-viral vectors for gene-based therapy. Nat Rev Genet. 2014;15(8): 541-555.
88. Davidson BL, McCray PB Jr. Current prospects for RNA interference-based therapies. Nat Rev Genet. 2011;12(5):329-340.
89. Kim H, Kim JS. A guide to genome engineering with programmable nucleases. Nat Rev Genet. 2014;15(5):321-334.
90. Tsai SQ, Zheng Z, Nguyen NT, et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat Biotechnol. 2015;33(2):187-197.
91. Urnov FD, Rebar EJ, Holmes MC, Zhang HS, Gregory PD. Genome editing with engineered zinc finger nucleases. Nat Rev Genet. 2010;11(9): 636-646.
92. Tebas P, Stein D, Tang WW, et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med. 2014;370(10): 901-910.
93. Coelho A, Picanço I, Seuanes F, Seixas MT, Faustino P. Novel large deletions in the human alph-globin gene cluster: Clarifying the HS-40 long-range regulatory role in the native chromosome environment. Blood Cells Mol Dis. 2010;45(2):147-153.
94. Ivanov M, Barragan I, Ingelman-Sundberg M. Epigenetic mechanisms of importance for drug treatment. Trends Pharmacol Sci. 2014;35(8): 384-396.
95. Helin K, Dhanak D. Chromatin proteins and modifications as drug targets. Nature. 2013; 502(7472):480-488.
96. Xie H, Xu J, Hsu JH, et al. Polycomb repressive complex 2 regulates normal hematopoietic stem cell function in a developmental-stage-specific manner. Cell Stem Cell. 2014;14(1):68-80.